This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Biocept Crescita futura

Future criteri di controllo 5/6

Si prevede che Biocept aumenterà gli utili e i ricavi rispettivamente del 65.8% e 53.1% all'anno, mentre si prevede che l'EPS crescerà del 66.4% all'anno.

Informazioni chiave

65.8%

Tasso di crescita degli utili

66.4%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	42.4%
Tasso di crescita dei ricavi	53.1%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	08 Jun 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:B00 - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	69	29	N/A	N/A	1
12/31/2024	19	-14	N/A	N/A	1
12/31/2023	7	-22	N/A	N/A	1
3/31/2023	7	-37	-19	-19	N/A
12/31/2022	26	-32	-14	-13	N/A
9/30/2022	41	-25	-9	-7	N/A
6/30/2022	57	-15	-5	-4	N/A
3/31/2022	63	-8	1	2	N/A
12/31/2021	61	-3	2	4	N/A
9/30/2021	66	2	-1	1	N/A
6/30/2021	55	-2	-7	-5	N/A
3/31/2021	44	-7	-15	-14	N/A
12/31/2020	27	-18	-21	-20	N/A
9/30/2020	11	-25	-25	-24	N/A
6/30/2020	6	-26	-24	-23	N/A
3/31/2020	6	-28	-24	-23	N/A
12/31/2019	6	-25	-24	-23	N/A
9/30/2019	5	-26	-23	-23	N/A
6/30/2019	4	-27	-23	-23	N/A
3/31/2019	3	-25	-22	-22	N/A
12/31/2018	3	-25	-23	-22	N/A
9/30/2018	3	-25	-23	-23	N/A
6/30/2018	4	-24	-23	-22	N/A
3/31/2018	4	-24	-23	-21	N/A
12/31/2017	5	-22	-21	-20	N/A
9/30/2017	5	-20	-19	-18	N/A
6/30/2017	5	-19	-17	-16	N/A
3/31/2017	5	-18	-16	-15	N/A
12/31/2016	3	-18	N/A	-16	N/A
9/30/2016	2	-19	N/A	-16	N/A
6/30/2016	1	-19	N/A	-16	N/A
3/31/2016	1	-18	N/A	-16	N/A
12/31/2015	1	-17	N/A	-15	N/A
9/30/2015	0	-16	N/A	-14	N/A
6/30/2015	0	-16	N/A	-14	N/A
3/31/2015	0	-15	N/A	-13	N/A
12/31/2014	0	-16	N/A	-15	N/A
9/30/2014	0	-14	N/A	-13	N/A
6/30/2014	0	-13	N/A	-11	N/A
3/31/2014	0	-12	N/A	-10	N/A
12/31/2013	0	-9	N/A	-6	N/A
9/30/2013	0	-10	N/A	-7	N/A
6/30/2013	0	-10	N/A	-7	N/A
3/31/2013	0	-11	N/A	-8	N/A
12/31/2012	0	-12	N/A	-9	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che B00 diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 0.4% ).

Guadagni vs Mercato: Si prevede che B00 diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede B00 diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di B00 ( 53.1% all'anno) crescerà più rapidamente del mercato German ( 5.6% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di B00 ( 53.1% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di B00 è previsto essere elevato tra 3 anni

This company is no longer active

Biocept Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

Full year 2022 earnings released: US$1.89 loss per share (vs US$0.19 loss in FY 2021)

No longer forecast to breakeven

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Investor sentiment improved over the past week

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: €6.05

New 90-day high: €5.10

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

New 90-day high: €4.80

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations

Biocept, Inc. Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, Including Cancer Cells

Biocept, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Biocept, Inc. Provides Update on COVID-19 Testing with More than 50,000 Specimens Received

New 90-day low: €3.62

Biocept, Inc. Announces That Highmark Has Made A Positive Coverage Determination on Target Selector Liquid Biopsy

New 90-day low: €3.69

Biocept, Inc. Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More Than 20,000 Specimens Processed

New 90-day low: €3.69

New 90-day low - €3.69

New 90-day low - €0.37

Biocept, Inc. Announces One-For-Ten Reverse Stock Split to Regain Compliance

First half earnings released

New 90-day high - €0.92

Biocept, Inc. to Report Q2, 2020 Results on Aug 12, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita